LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About ...

Brett Monia, Ph.D. Chief Executive Officer Holly Kordasiewicz, Ph.D. Chief Development Officer YE:2025 Business Update and Financial Results February 25, 2026 Nasdaq: IONS 1 On Today's Earnings Call Beth Hougen Chief Financial Officer Eugene Schneider, M.D. Chief Clinical Development Officer 2 Eric Swayze, Ph.D. Executive Vice President, Research Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial pote ...

EQT backs out of takeover bid for UK's Oxford Biomedica | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A view shows EQT AB's logo at the company's office in Tokyo, Japan May 13, 2025. REUTERS/Miho Uranaka [Purchase Licensing Rights, opens new tab]Feb 25 (Reuters) - Private equity group EQT [(EQTAB.ST), opens new tab] said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica [(OXB.L), opens new tab] ...

4Q & FY 2025 Financial Results & Business Update To add/change the picture: Transformative immunomodulating medicines for patients • Click on the image and press BACKSPACE or DELETE on the keyboard > Click on the icon at the centre of the placeholder > Select the chosen image • To adjust the crop, right-click on the image > Crop • If for any reason the image placeholder loses the rounded shape, click on Reset button in the Home tab at the top. To add/change the picture: • Click on the image and press BACKSP ...

BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care ConferenceFormat: ...

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA. Members of the Artiva management team will also be availab ...

Important Information This presentation of Recursion Pharmaceuticals, Inc. ("Recursion," "we," "us," or "our") and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "potential," "predicts," "projects," "seeks," "should," "will," or words of similar meaning and include, but are not limited to, statem ...

Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailabilityNovo Nordisk will lead global development and commercialization, and Vivtex is eligible to receive up to 2.1 billion US dollars, as well as royalties on net sales of future productsPartnership expands Vivtex’s platform to metabolic diseases and supports Novo Nordisk’s mission to deliver scalable and innovative medicines to people with obesi ...

AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details TD Cowen 46th Annual Health Care Conferen ...

With a market cap of $206.4 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics for serious diseases worldwide. Headquartered in Thousand Oaks, California, Amgen serves healthcare providers globally and collaborates with major biopharmaceutical partners to expand and advance its pipeline. Companies valued at $200 billion or more are generally considered “mega-cap” stocks, and Amgen fits this criterion perfectly. I ...